Online inquiry

IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2601MR)

This product GTTS-WQ2601MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets MPL gene. The antibody can be applied in Chronic immune (idiopathic) thrombocytopenic purpurea (ITP) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_005373.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4352
UniProt ID P40238
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ2601MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12964MR IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA PDL 192
GTTS-WQ2701MR IVTScrip™ mRNA-Anti-CD19&CD3E, AMG103(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG103
GTTS-WQ15532MR IVTScrip™ mRNA-Anti-TGM2, UCB-7858(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA UCB-7858
GTTS-WQ7477MR IVTScrip™ mRNA-Anti-TGFB, GC-1008(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GC-1008
GTTS-WQ14649MR IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SC0001-SCX
GTTS-WQ6091MR IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CNTO-1959
GTTS-WQ8992MR IVTScrip™ mRNA-Anti-IL13, IMA-638(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMA-638
GTTS-WQ15167MR IVTScrip™ mRNA-Anti-CD6, T1h(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA T1h
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW